Although no changes in inRNA levels for GAPDH were evident in rats with THE HEART RESPONDS TO INCREASED stressarising from pressure overload by inducing cardiac myocyte hypertrophy where various growth promoting factors such as angiotensin II, endbthelin I, as well as both a-and n-adrenergic agonists, have now been identified to play a role in increasing the muscle mass (1) (2) (3) (4) . Although cardiac hypertrophy is an adaptive process at initial stages, increased myocardial muscle mass over a prolonged period is known to result in cardiac dysfunction and heart failure (4) . In fact, the activation of so-called "fetal genes" including skeletal a-actin, atnal natriuretic peptide, and -myosin heavy chain has been reported in pressureoverloaded hypertrophied heart (1, 5, 6 (14, 15) .
A promising group of compounds that reduce the activity of mitochondrial carnitine palmitoyltransferase-1 (CPT-1) and thereby shiftfuel metabolism of the heart in the directionof glucose oxidation (16) has been reported to induce cardiac growth. The CP'f-l inhibitor etomoxir was found to increase the expression of myosin Vi in a manner similarto that seen in hyperthyroidism (17 Because the expression of skeletal a-actin has been reported to increase in cardiac hypertrophy due to pressure overload (5, 21) as well as in cardiomyocytes in culturein the presence of a-adrenergic agonists (22) , the effect of etomoxir on mRNA abundance for skeletal a-actin was examined. (Table 1) . When rats with aorticconstriction were treated with etomoxir, the hypertrophy of the leftventriclewas increased to 43% (Table 1) .In contrast to the degree of cardiac hypertrophy in pressure-overloaded, etomoxir-treated animals, the level of gene expression of SR proteins was not affected in an additive manner.
METHODS

Experimental model
In rats with pressure-overloaded left ventricle, SERCA2 mRNA level was significantlyreduced when normalized with 18 S rRNA or poly(A)+ mRNA (Fig. 1) . Although etomoxir treatment did not induce any significant change in SERCA2 mRNA abundance in sham-operated animals, it prevented the reduction in SERCA2 mRNA levels due to pressure overload in rats (Fig. 1) . In fact, when the SERCA2 mRNA level was normalized by 18 S rRNA, the etomoxir treatment resulted in a significant increase of SERCA2 compared to the untreated pressure-overloadedrats (Fig. 1) .The pressure overload I I Bft I did not produce a significant reduction in SERCA2 protein content in control SR as assessed by the Western blot analysis; however, the SERCA2 protein abundance was increased by etomoxir in the pressure-overloadedleft ventricle (Fig. 2) . The mRNA abundance of SR PLP was also reduced in the pressure-overloaded heart (Fig. 3A) , but the etomoxir-treated rats with pressure overload did not exhibit a significant reduction in PLP mRNA level. Indeed, a significant increase in PLP mRNA level when normalized with 18 S rRNA was evident upon treating the pressure-overloaded rats with etomoxir (Fig. 3A) . The mRNA abundance of CRC was significantly reduced by pressure overload in control animals when normalized with poly(A) + mRNA or 18 S rRNA (Fig. 3B) .
Although in etomoxir-treated rats with pressure overload, the mRNA level for CRC was not significantly increased in comparison to the untreated pressure-overloaded animals, these levels were not significantly different from the sham control values (Fig. 3B) .
When the CRC mRNA values were normalized with those for GAPDH mRNA, a significant increase in the relative CRC mRNA level was observed in etomoxir-treated, pressure-overloaded rats compared to the untreated pressure overload group ( Table   1 ).
The abundance of skeletal -actin was significantly increased in rats with pressure overload, which was prevented by the etomoxir treatment (Fig. 'IA) . In contrast to SR proteins and skeletal U-actin mRNA, no significant changes were observed in GAPDH gene expression upon inducing pressure overload (Fig. 4B) . When the mRNA levels for SR SERCA2 and PLP were analyzed by slot blot and normalized with GAPDH mRNA, pressure overload was observed to depress the expression for SERCA2 and PLP SR proteins in sham control but not in etomoxirtreated animals (Table 1) . Results for SERCA2 and GAPDH mRNA obtained by slotblot analysiswere also confirmed by using the Northern blot analysis (Fig. 5) .
Normalization of SERCA2 mRNA with respect to GAPDH mRNA performed by the Northern blot analysis revealed that the relative abundance of SERCA2 mRNA level was decreased by 39% in hypertrophied heart. This change was prevented by treatment with etomoxir, and in fact an increase (P< 0.05) in SERCA2 mRNA was evident upon treating the pressure-overloaded rats with etomoxir. The response of the cardiomyocyte to mechanical stress involves an increase in cellular mass as well as restructuring of intracellular components; these changes in phenotypic expression are considered to be under genetic transcriptional control. In mild hypertrophy of short duration, the SERCA2 mRNA level and protein content were unchanged (32, 33) , whereas the steady-state levels of SERCA2 mRNA and protein content were decreased in chronically pressure-overloaded hearts (11, 34, 37 ported in patients with idiopathic dilated cardiomyopathy and congestive heart failure (35) . In accordance with these observations, the steady-state levels of SERCA2 mRNA were decreased in the present rat model of chronic pressure overload. The Western blot analysis revealed that reduction in the level of the SERCA2 protein was not significant in the pressure-overloaded hearts, and this can be taken to indicate that the steady-state level of mRNA for SERCA2 was affected to a greater extent. The present data also support the view that the depressed SR Ca2 +ATPase activity and subsequent reduced rate of relaxation in pressure-overloaded hearts (8, 33) are at least in part due to a decreased synthesis and/or stability of the SERCA2 mRNA. In this study, mRNA levels for SR PLP and CRC were also decreased in the pressure-overloaded hearts, in agreement with previous findings in different types of heart disease (7, 38) . These depressed mRNA levels for SR CRC and PLP can also be seen to explain the impaired contractile function of the hypertrophied heart as a consequence of defects in the SR Ca2+ release process as well as in the regulationof SR Ca2 + transport activity, respectively (7). When control rats were treated with a high dose of etomoxir, the weights of leftand right ventricleswere increased in a proportionate manner (8, 19) . Belause the etomoxir-induced cardiac hypertrophy was prevented by feeding a dietcomposed of medium-chain fattyacids that bypass the CPT-1 inhibition, it was suggested that the action of etomoxir on the heart may be due to the inhibition of CPT-1, which provides a link with cardiac energy metabolism (17, 19) .
DISCUSSION
Because inhibition of CP1'-l by etomoxir mimics an anabolic state,i.e.,CPT-1 inhibition due to high malonyl-CoA abundance (16), it is not unexpected that high doses of etomoxir were associated with a proportionate growth of the left and right heart chambers (18, 19) . The data in the present study demonstrate that treatment of control animals with etomoxir resulted in a mild cardiac hypertrophy that was not associatedwith a significant reduction in the expression of mRNA encoding SERCA2, PLP, and CRC proteins.On the other hand, when rats with pressure-overloaded hypertrophied hearts were treated with etomoxir,a significant decrease in the levels of SERCA2, PLP, and CRC mRNA was not observed. In fact, a significant increase in mRNA levels for SERCA2 and CRC was observed from treating the pressure-overloaded hearts with etomoxir. Although cardiac hypertrophy due to pressure overload was increased further by treatment of animals with etomoxir, the unfavorable effectsof pressure overload on gene expressionwere prevented.Such a conclusion is supported by the finding that the increase in a-skeletalactin expressed in the fetal heart, unlike the adult heart (5, 21, 22), due to pressure overload was prevented by the treatment of animals with etomoxir.
The beneficial effect of etomoxir at the level of mRNA expression for SERCA2, PLP, and CRC proteins may account for the maintenance of SR function and improvement of cardiac performance in heart disease. Furthermore, the beneficialeffectsof etomoxir on SR and contractile proteins (8, (17) (18) (19) were evident without any reduction in the magnitude of cardiac hypertrophy due to pressure overload.This would mean that drugs such as etomoxir show great potential in preventing the deterioration of mechanisms associated with cardiac dysfunction in hypertrophied heart. In view of the fact that etomoxir has been shown to inhibitthe oxidationof freefattyacids and promote the oxidationof glucose (8, 16, 19, 20) , itis feasiblethat a shiftin fuel utilization in the myocardium by etomoxir may increase the mRNA levelsfor SR proteins in the hypertrophied heart, and thus may prove helpful in preventing the transitionof cardiac hypertrophy into heart failure.
The molecular mechanisms by which etomoxir leads to an increase in the steady-state mRNA levels for SR proteins may include an increase transcriptional rateand/or a decrease in the mRNA turnover. A) The 
